ContractCollaboration Agreement • May 10th, 2006 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES EXCHANGE ACT OF 1933, AS AMENDED.
AMENDMENT TO COLLABORATION AGREEMENTCollaboration Agreement • May 10th, 2006 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
This AMENDMENT TO COLLABORATION AGREEMENT (the “Amendment”) by and between ONYX PRARMACEUTICAIS, INC., a California corporation having its principal place of business in Richmond, California (“Onyx”) and BAYER CORPORATION, an Indiana corporation having its principal place of business in Pittsburgh, Pennsylvania (“Bayer”), shall be effective as of the date of last execution below. Each of Bayer and Onyx are sometimes referred to herein as the “Party” or, collectively, as the “Parties”.
AMENDMENT TO COLLABORATION AGREEMENT BETWEEN ONYX PHARMACEUTICALS, INC. AND BAYER CORPORATIONCollaboration Agreement • May 10th, 2006 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
This Amendment to the Collaboration Agreement (the “Second Amendment”) is dated February 1, 1999 (“the Effective Date of the Second Amendment”) by and between ONYX PHARMACEUTICALS, Inc., a California corporation having its principal place of business in Richmond, California (“Onyx”) and BAYER CORPORATION, an Indiana corporation having its principal place of business in Pittsburgh, Pennsylvania (“Bayer”). Bayer and Onyx may be referred to herein individually as “Party,” or collectively, as the “Parties.”
ContractCollaboration Agreement • May 10th, 2006 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES EXCHANGE ACT OF 1933, AS AMENDED.
U.S. CO-PROMOTION AGREEMENT BAYER PHARMACEUTICALS CORPORATION and ONYX PHARMACEUTICALS, INC. March 6, 2006Promotion Agreement • May 10th, 2006 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California
This U.S. CO-PROMOTION AGREEMENT (this “Agreement”) is entered into as of this 6th day of March, 2006 between BAYER PHARMACEUTICALS CORPORATION, a Delaware corporation (“Bayer”) and ONYX PHARMACEUTICALS, INC., a Delaware corporation (“Onyx”).
